A Phase II Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase II Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2016

At a glance

  • Drugs Amrubicin (Primary) ; Carboplatin (Primary) ; Pegfilgrastim
  • Indications Small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Apr 2015, as reported by ClinicalTrials.gov.
    • 10 Sep 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top